Chlorhydric acid pirenzepine solid preparation for eye-dripping and matching dissolvent thereof

Abstract

The invention discloses an alcaine flat sour solid agent of eye and allocating solvent, which is composed of one of alcaine flat sour, filler, addictive and disintegration agent, wherein the eye drop is allocated by mated solvent, pure water, pH adjuster, osmotic pressure modifier, adhering modifier and conservative through swaying evenly.

Description

1. Technical field [0001] The invention belongs to pharmaceutical preparations, in particular to pharmaceutical preparations containing organic active ingredients. 2. Background technology [0002] Pirenzepine hydrochloride is a selective M1 receptor antagonist, which is currently clinically used to treat gastric diseases such as gastric and duodenal ulcers. Studies in recent years have shown that pirenzepine can inhibit the occurrence and development of myopia, and its effect is better than that of atropine. The selective application of pirenzepine to the eye can significantly inhibit the growth of eyeballs in animals, with definite curative effect and small side effects, and has potential application value in the prevention and treatment of juvenile myopia. [0003] In the prior art, there was a CN1509172A patent application published on June 30, 2004, which is a water-based ophthalmic preparation for the treatment of myopia, which contains pirenzepine and a certain amoun...

AI Technical Summary

Problems solved by technology

After searching, there is no open technical literature on the solid preparation of pirenzepine hydrochloride for eye drops and its supporting solvent at home and abroad, nor any ophthalmic solid preparation products containing pirenzepine hydrochloride listed on the market